Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

AIDS

Volumn 13, Issue 18, 1999, Pages 2541-2546

  Verhofstede, Chris ^a,b   Van Wanzeele, Filip ^b   Van Der Gucht, Bea ^b   De Cabooter, Nancy ^a   Plum, Jean ^a  

^a AIDS Reference Laboratory   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antiretroviral therapy; HIV resistance mutations; HIV sequence variability

Indexed keywords

LAMIVUDINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; ZIDOVUDINE;

EID: 0033389039     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912240-00007     Document Type: Article

References (17)

1. 1. Larder BA, Kellam P, Kemp SD. Zidovudine-resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5:137-144.
2. 2. Schinazi RF, Larder BA, Mellors J. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997, 5:129-142.
3. 3. Deeks SG, Parkin N, Petropoulos CJ et al. Correlation of baseline phenotypic drug susceptibility with 16 weeks virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy. Antiviral Ther 1998, 3:36-37.
4. 4. Harrigan PR, Hertogs K, Verbiest W et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999, 13:1863-1871.
5. 5. Frenkel LM, Wagner LE II, Atwood SM, Cummins TJ, Dewhust S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995, 33:342-347.
6. 6. Stuyver L, Wyseur A, Rombout A et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997, 41:284-291.
7. 7. Kellam P, Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
8. 8. Hirsch MS, Conway B, D'Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection - implications for clinical management. JAMA 1998, 279:1984-1991.
9. 9. Back NK, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
10. 10. de Jong MD, de Boer RJ, de Wolf F et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84.
11. 11. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouzioux C, Viard J-P. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS 1998, 12:2358-2359.
12. 12. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72:7632-7637.
13. 13. Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN. Rebound of HIV-1 viral load after suppression to very low levels. AIDS 1998, 12:2360.
14. 14. Albert J, Wahlberg J, Lundeberg J et al. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. J Virol 1992, 66:5627-5630.
15. 15. Land S, McGavin K, Lucas R, Birch C. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J Infect Dis 1992, 166:1139-1142.
16. 16. Yerly S, Rakik A, De Loes SK et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998, 72:3520-3523.
17. 17. Izopet J, Bicari-See A, Pasquier C et al. Mutations conferring resistance to zidovudine diminish the virologic response to stavudine plus didanosine therapy. Int Conf AIDS 1998, 12:581-582 [Abstract no. 32306].